CYH (CYH) EVP granted shares and options, with some stock withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Community Health Systems EVP Kevin A. Stockton reported multiple equity compensation moves in common stock and derivatives on March 1, 2026. He exercised 50,000 performance-based restricted shares and received new grants of 60,000 performance-based restricted shares and 30,000 stock options, all at a stated price of $0.00 per share. He also acquired 50,000 common shares through a derivative exercise and 30,000 additional restricted common shares, then had 35,573 common shares withheld at $3.46 per share to cover tax obligations. Following these transactions, he directly held 208,290 common shares. Footnotes explain that vesting of the performance-based awards depends on the company’s achievement of specified EBITDA and net revenue growth goals over performance periods running from 2024–2026, 2025–2027, and 2026–2028, with actual vesting ranging from 0% to 200% of target based on results.
Positive
- None.
Negative
- None.
Insider Trade Summary
50,000 shares exercised/converted
Mixed
15 txns
Insider
STOCKTON KEVIN A
Role
EVP, Operations & Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Based Restricted | 50,000 | $0.00 | -- |
| Grant/Award | Performance Based Restricted | 60,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to Buy) | 30,000 | $0.00 | -- |
| Exercise | Common Stock | 50,000 | $0.00 | -- |
| Grant/Award | Common Stock | 30,000 | $0.00 | -- |
| Tax Withholding | Common Stock | 35,573 | $3.46 | $123K |
| holding | Performance Based Restricted | -- | -- | -- |
| holding | Performance Based Restricted | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Performance Based Restricted — 0 shares (Direct);
Stock Options (Right to Buy) — 30,000 shares (Direct);
Common Stock — 213,863 shares (Direct)
Footnotes (1)
- The vesting of these performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 100% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023. The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period. The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period.
FAQ
What insider transactions did CYH EVP Kevin Stockton report on March 1, 2026?
Kevin Stockton reported equity compensation activity including option exercises, new grants, and tax withholding. He exercised 50,000 performance-based restricted shares, received 60,000 new performance-based restricted shares and 30,000 stock options, and had 35,573 common shares withheld for taxes.
What stock option grants did Kevin Stockton receive from Community Health Systems (CYH)?
Kevin Stockton received grants of 30,000 stock options described as a right to buy Community Health Systems common stock. These options were awarded at a stated price of $0.00 in the filing, and vesting occurs in one-third increments on the first, second, and third anniversaries of the grant date.